Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera

Journal of Medical Virology

Volumn 59, Issue 2, 1999, Pages 169-179

  Lawoko, Alex Lumoi ^a,b,g   Johansson, B ^c   Hjalmarsson, S ^b   Christensson, B ^d   Ljungberg, B ^d   Al Khalili, L ^f   Sjolund M ^b   Pipkorn, R ^e   Fenyo E M ^f   Blomberg, J ^b  

^a LUND UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c HELSINGBORG HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f KAROLINSKA INSTITUTE   (Sweden)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anti V3 IgG peptide ELISA; Neutralisation in vitro; V3 sequences

Indexed keywords

ANTIVIRAL ACTIVITY; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; NONHUMAN; RABBIT; VIRUS ISOLATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; RABBITS; SEQUENCE HOMOLOGY, AMINO ACID;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS; RNA VIRUSES;

EID: 0032839838     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199910)59:2<169::AID-JMV8>3.0.CO;2-1     Document Type: Article

References (50)

1. Albert J, Abrahamsson B, Nagy K, Aurelius E, Gaines H, Nyström G, Fenyö EM 1990. Rapid development of isolate specific neutralising antibodies in primary HIV-1 infection and consequent emergence of virus variants which resist neutralisation by autologous sera. AIDS 4:107-112.
2. Albert J, Fenyö EM 1990. Simple, sensitive, and specific detection of HIV in clinical specimens by polymerase chain reaction with nested primers. J Clin Microbiol 28:1560-1564.
3. Blomberg J, Nilsson I, Andersson M 1983. Viral antibody screening system that uses standardised single immunoglobulin G enzyme immunoassay with multiple antigens. J Clin Microbiol 17:1081-1091.
4. Blomberg J, Lawoko AL, Pipkorn R, Moyo S, Malmvall BE, Shao J, Dash R, Tswana S 1993. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian, and Swedish HIV-1 positive sera. AIDS 7:759-767.
5. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J 1990. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 28:495-503.
6. Boudet F, Lasarte JJ, Sarobe P, Borras-Cuesta F, Theze J 1996. Fine analysis of immunoreactivity of V3 peptides: antibodies specific for V3 domain of laboratory HIV-1 strains recognise multiple V3 sequences synthesised from field HIV type 1 isolates. AIDS Res Hum Retroviruses 12:1671-1679.
7. Cheingsong-Popov R, Lister S, Callow D, Kaleebu P, Beddows S, Weber J and the WHO Network for HIV Isolation and Characterisation 1994. Serotyping HIV type 1 by antibody binding to the V3 loop: relationship to viral genotype. AIDS Res Hum Retroviruses 10:1379-1386.
8. Cheingsong-Popov R, Williamson C, Lister S, Morris L, van Harmelen J, Bredell H, Wood R, Sonnenberg P, van der Ryst E, Martin D, Weber J 1998. Usefulness of HIV-1 V3 serotyping in studying the HIV-1 epidemic in South Africa. AIDS 12:949-950.
9. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P 1996. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nature Medicine 2:1244-1247.
10. Coeffier E, Excler JL, Kieny MP, Meignier B, Moste C, Tartaglia J, Pialoux G, Salmon-Ceron D, Leclerc C 1997. Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccines. AIDS Res Hum Retroviruses 13:1471-1485.
11. Dayhoff MO, Barker WC, Hunt LT 1983. Establishing homologies in protein sequences. Methods Enzymol 91:524-549.
12. Ekstrand DHL, Awad RJ, Källander KF, Gronowitz JS 1996. A sensitive assay for the quantification of reverse transcriptase activity based on the use of carrier-bound template and non-radioactive product detection, with special reference to human immunodeficiency virus isolation. Biotechnol Appl Biochem 23:95-105.
13. Fenouillet E, Blanes N, Benjouad A, Gluckman JC 1995. Anti-V3 antibody reactivity correlates with clinical stage of HIV-1 infection and with serum neutralising activity. Clin Exp Immunol 99:419-424.
14. Fenyö EM, Albert J, McKeating J 1996. The role of humoral responses in HIV infection. AIDS 10:S97-S106.
15. Gausepohl H, Boulin C, Kraft M, Frank RW 1992. Automated multiple peptide synthesis. Peptide Res 5:315-320.
16. Global Programe on AIDS. 1994. WHO Guidlines for Standard HIV isolation Procedures.
17. Goudsmit J. Immunochemistry of AIDS. 1993. In: Norrby E, editor. Chemical immunology. Basel. Karger; p 56:1-33.
18. Haynes BF, Pantaleo G, Fauci AS 1996. Toward an understanding of the correlates of protective immunity to HIV infection. Science 271:324-328.
19. Hogervost E, Jurriaans S, de Wolf F, van Wijk A, Wiersma A, Valk M, Roos M, van Gemen B, Coutinho R, Miedema F, Goudsmit J 1995. Predictors for non-and slow progression in human immunodeficiency virus type-1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24 specific but not V3-specific antibody levels. J Infect Dis 171:811-821.
20. Javaherian K, Langlois AJ, Mcdanal C, Ross LK, Eckler LI, Jellis CL, Profy AT, Rusche JR, Bolognesi DP, Putney SD, Matthews TJ 1989. The principal neutralisation determinant of human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci USA 86:6768-6772.
21. Javaherian K, Langlois AJ, LaRosa GJ, Profy AT, Bolognesi DP, Herlihy WC, Putney SD, Matthews TJ 1990. Broadly neutralising antibodies elicited by the hypervariable neutralising determinant of HIV-1. Science 250:1590-1593.
22. Klasse PJ, Pipkorn R, Blomberg J 1988. Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 are strongly associated with health among HIV-positive subjects. Proc Natl Acad Sci USA 85:5225-5229.
23. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowski W, Farthing C, Ho DD 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 69:4650-4655.
24. Lawoko AL, Johansson B, Dash R, Falck L, Dietrich U, Pipkorn R, Nilehn B, Blomberg J 1995. Continuity and discontinuity in the anti-V3 IgG response of human immunodeficiency virus type 1 infected persons in a cross-sectional and longitudinal study using synthetic peptides. J Infect Dis 172:682-690.
25. McKeating JA, Gow J, Goudsmit J, Pearl LH, Mulder C, Weiss RA 1989. Characterisation of HIV-1 neutralisation escape mutants. AIDS 3:777-784.
26. Milich L, Margolin B, Swanstrom R 1993. V3 loop of human immunodeficiency virus type 1 Env protein: interpreting sequence variability. J Virol 67:5623-5634.
27. Milich L, Margolin B, Swanstrom R 1997. V3 loop of the human immunodeficiency virus type 1 env protein: interpretation of sequence variability. Virology 239:108-118.
28. Moore JP 1993. The reactivities of HIV-1+ human sera with solid-phase V3 peptides can be poor predictors of their reactivities with V3 loops on native gp120 molecules. AIDS Res Hum Retroviruses 9:209-219.
29. Moore JP, Cao Y, Coley A, Wyatt R, Robinson J, Gorny M, ZollaPazner S, Ho DD, Koup RA 1994. Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid phase peptide binding assays. J Acquired Immune Def Syndromes 7:332-339.
30. Myers G, Foley B, Mellows JW, Korber B, Jeang KT, Wain-Hobson S 1996. Human retroviruses and AIDS: a compilation and analysis of nucleic acid and amino acid sequences. Los Alamos, NM: Los Alamos National Laboratory.
31. Nara PL, Smit L, Dunlop N, Hatch W, Merges M, Waters D, Kelliher J, Gallo RC, Fischinger PJ, Goudsmit J 1990. Emergence of viruses resistant to neutralisation by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J Virol 64:3779-3791.
32. Nara P, Garrity R, Minassian A, Goudsmit J 1992. Envelope plasticity outside the V3 and gp120-CD4 binding epitopes results in resistance to neutraliztion and fusion without loss of antibody binding: Implications to HIV-1 vaccine design. In: Vaccines 92: modern approaches to new vaccines including prevention of AIDS. Brown F, Chanock R, Ginsberg HS, Lerner R, editors. NY: Cold Spring Harbor Laboratories, Cold Spring Harbor, p 175:181.
33. Poss M, Rodrigo AG, Gosink JJ, Learn GH, De Vange Panteleeff D, Martin Jr. HL, Bwayo J, Kreiss JK, Overbaugh J 1998. Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1. J Virol 72:8240-8251.
34. Redfield R, Wright CD and Tramont CE 1986. The Walter Reed staging classification for HTLV-III/LAV infection. New Eng J Med 314:131-132.
35. Revised classification for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults 1992. Centers for Disease Control and Prevention MMWR 41:RR-17.
36. Salminen MO, Koch C, Sanders-Buell E, Ehrenberg PK, Michael NL, Carr JK, Burke DS, McCutchan FE 1995. Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction. Virology 213:80-86.
37. Sawyer LA, Katzenstein DA, Hendry MR, Boone EJ, Vujcic KL, Williams CC, Zeger SL, Saab AJ, Rinaldo CR Jr., Phair JP, Giorgi VJ, Quinnan GV Jr. 1990. Possible beneficial effects of neutralising antibodies and antibody-dependent, cell mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res Hum Retroviruses. 6:341-356.
38. Scarlatti G, Leitner T, Hodara V, Jansson M, Karlsson A, Wahlberg J, Rossi P, Uhlen M, Fenyo EM, Albert J 1996. Interplay of HIV-1 phenotype and neutralising antibody response in pathogenesis of AIDS. Immunol Lett 51:23-28.
39. Schreiber M, Peterson H, Wachsmuth C, Muller H1 Hufert F, Schmitz H 1994. Antibodies of symptomatic HIV-1 infected individuals are directed to the V3 domains of non-infectious and not infectious virions present in autologous serum. J Virol 68:3908-3916.
40. Schreiber M, Muller H, Wachsmuth T, Laue F, Hufert T, Van Laer MD 1997a. Escape of HIV-1 is associated with lack of V3 domain specific antibodies in vivo. Clin Exp Immunol 107:15-20.
41. Schreiber M, Wachsmuth C, Muller H, Odemuyiwa S, Schmitz H, Meyer S, Meyer B, Schneider-Mergener J 1997b. The V3-directed immune response in natural human immunodeficiency virus type-1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain. J Virol 71:9198-9205.
42. Vancott TC, Polonis VR, Loomis LD, Michael NL, Nara PL, Birx DL 1995. Differential role of V3-specific antibodies in neutralisation assays involving primary and laboratory adapted isolates of HIV type 1. AIDS Res Hum Retroviruses 11:1379-1391.
43. Vogel T, Kurth R, and Norley S 1994. The majority of neutralising Abs in HIV-1 infected patients recognise linear V3 loop sequences. Studies using HIV-1 MN multiple antigenic peptides. J Immun. 153:1895-1904.
44. Von Gegerfeldt A, Albert J, Morfeldt-Månson L, Broliden C, Fenyö EM 1991. Isolate specific neutralising antibodies in patients with progressive HIV-1 related disease. Virology 185:162-168.
45. Weber J, Fenyö EM, Beddows S, Kaleebu P, Björndahl Å 1996. Neutralisation serotypes of human immunodeficiency virus type 1 are not predicted by genetic subtype: the WHO Network for HIV Isolation and Characterisation. J Virol 70:7827-7832.
46. Wyatt R and Sodroski J 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884-1888.
47. Yamaguchi Y, Gojobori T 1997. Evolutionary mechanisms and population dynamics of the third variable envelope region of HIV within single hosts. Proc Natl Acad Sci USA 94:1264-1269.
48. Yamanako T, Fugimuru Y, Ishimoto S, Yoshioka A, Konishi M, Narita Mimaya J, Meguru T, Nakasone T, Okamoto Y, Yoshizaki H, Yamada K, Honda M 1997. Correlation of titre of antibody to principal neutralisation domain of HIV-1 MN strain with disease progression in Japanese Hemophiliacs seropositive for HIV type 1. AIDS Res Hum Retroviruses. 13:317-326.
49. Zhang Y, Fracasso C, Fiore RJ, Björndahl Å, Angarano G, Gringeri A, Fenyö EM 1997. Augmented serum neutralising activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1 infected long-term nonprogressors. J Infect Dis 176:1180-1187.
50. Zvi A, Fiegelson DJ, Hayek Y, Anglister J 1997. Conformation of the principal neutralising determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralising antibody studied by two dimensional nuclear magnetic resonance difference spectroscopy. Biochem 36:8619-8627.